Essais liés10clinical trials
VilleBrnolocalisation
PaysCzechialocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06392386

Ouvrir le site du centre

Essais cliniques associés

10
MoléculeIndication / populationPhaseNCTTitreStatut
Tacabrutideg Cancer Phase 3 NCT06846671 CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors RECRUITING
Sonrotoclax Cancer Phase 3 NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia RECRUITING
Sotorasib Cancer Phase 3 NCT05920356 A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) RECRUITING
Efgartigimod PH20 SC Myasthénie Phase 2/3 NCT06392386 ADAPT Jr SC — A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis RECRUITING
Telitacicept Myasthénie Phase 3 NCT06456580 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) RECRUITING
Nipocalimab Myasthénie Phase 3 NCT04951622 A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis RECRUITING
Efgartigimod IV Myasthénie Phase 3 NCT06298552 ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT05269004 OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Interferon beta-1a SEP Phase 3 NCT01412333 A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis COMPLETED
Efgartigimod PH20 SC Myasthénie Phase 3 NCT06558279 ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis ACTIVE_NOT_RECRUITING